Sign In
Buy NCNA
$2.03
-0.0400 (-1.93%)
At Close: Jun 03, 2026
Aurion Biotech Appoints Donald Munoz as Chief Financial Officer
07:00am, Monday, 10'th Feb 2025
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced toda
NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update
07:00am, Monday, 25'th Nov 2024
Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for Medical Oncology (ESMO) Congress 2024
Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival Foll
Baillie Gifford's Strategic Acquisition of NuCana PLC Shares
12:03pm, Friday, 04'th Oct 2024
On September 1, 2024, Baillie Gifford (Trades, Portfolio), a prominent investment management firm, expanded its portfolio by acquiring 917,600 shares of NuCana PLC, a UK-based biopharmaceutical compan
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
04:01pm, Wednesday, 25'th Sep 2024
EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-773
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
12:11pm, Tuesday, 17'th Sep 2024
NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.
Combination of NUC-7738 plus Pembrolizumab Resulted in Prolonged Progression Free Survival, a Compelling Disease Control Rate including Partial Responses, and a Favorable Safety Profile Combination of
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study
04:01pm, Thursday, 29'th Aug 2024
NuTide:323 Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
04:01pm, Thursday, 15'th Aug 2024
Key Data Readouts on Track for All Programs in 2024 Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial resu
NuCana to Present at the Jefferies Global Healthcare Conference
08:36am, Thursday, 30'th May 2024
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-o
NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit
08:00am, Tuesday, 21'st May 2024
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
04:01pm, Thursday, 16'th May 2024
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Canc
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
04:01pm, Wednesday, 01'st May 2024
EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification L
NUC-7738 Reprograms Cancer Cell Lipid Metabolism to Make Tumors Less Aggressive and Promote Cancer Cell Death
NuCana Announces Plan to Implement ADS Ratio Change
04:30pm, Wednesday, 27'th Mar 2024
EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from o
